摘 要 目的：探讨孟鲁司特治疗咳嗽变异性哮喘(CVA)的临床疗效。方法：260例 CVA患者随机分成观察组与对照组各130例。对照组给予口服盐酸丙卡特罗和氯雷他定，观察组在对照组基础上加用孟鲁司特咀嚼片。丙卡特罗、氯雷他定用至临床症状与体征消失，孟鲁司特总疗程3个月。观察疗效、复发率及不良反应情况。结果：与对照组相比，观察组患者临床症状缓解时间、消失时间均明显缩短(分别为P＜0.05、P＜0.01)。观察组与对照组临床总有效率分别为82.3%、66.2% (P＜0.01)，复发率分别为6.2%、14.6% (P＜0.01)。观察组不良反应发生率低且轻微。结论：孟鲁司特治疗CVA安全有效，复发率低。

　　关键词咳嗽变异性哮喘 孟鲁司特 白三烯受体拮抗剂

　　中图分类号：R974.3；R562.25 文献标识码：A 文章编号：1006-1533(2011)09-0439-03

　　Clinical efficacy of montelukast in the treatment of cough variant asthma

　　ZENG Xiao-chun

　　（Chongqing DonghuaHospital，Chongqing，400032）

　　ABSTRACTObjective: To investigate the effect of montelukast on the treatment of cough variant asthma (CVA). Methods: 260 patients with CVA were randomly divided into observation group and control group ，each with 130 cases. Control group was given oral procaterol hydrochloride and loratadine，and observation group was given montelukast chewable tablets for total three months on the basis of treatment of control group. Efficacy，relapse rate and adverse reactions were observed. Results: Compared with the control group，timefor the relief and disappearance of symptom in observation group was much shorter (P＜0.05，P＜0.01，respectively). The total effective rates of the observation group and control group were 82.3% and 66.2%，respectively (P＜0.01)，and the recurrence rates were 6.2% and 14.6%，respectively (P＜0.01). The adverse reaction in observation group was low and mild. Conclusion: Montelukast is safe and effective in the treatment of CVA with a low recurrence rate.

　　KEY WORDScough variant asthma；montelukast；procaterol；loratadine

　　咳嗽变异性哮喘(cough variant asthma, CVA)是一种“只咳不喘”的不典型哮喘，主要表现为慢性的持续性咳嗽，双肺听诊无哮鸣音，临床上常被误诊为上呼吸道感染、支气管炎，但反复应用抗生素疗效不佳。（剩余1566字）

中华医学之家：http://www.xinxi85.com

投稿信箱：zhyxzj85@163.com

联系电话：029--85327298     主编QQ：693891972